If this test shortens that gap, even by a little, that's meaningful
In the long human effort to understand the minds of children who experience the world differently, a team of researchers at Arizona State University has found a possible new doorway: a urine test that reads the chemical language of the gut to detect early signs of autism. By measuring seventeen microbial metabolites, the test identified ninety percent of children with autism while sparing typically developing children from false alarms — a result that points not only toward earlier diagnosis, but toward a reframing of autism as a condition rooted in biology rather than behavior or blame. The work, born partly from a parent's own experience, arrives at a moment when one in thirty-one American children carries an autism diagnosis, and when the weight of waiting for answers is itself a kind of harm.
- Families navigating autism diagnosis often endure months or years of uncertainty before behavioral assessments yield answers — a delay with real developmental consequences for children.
- A simple urine test detecting gut-derived metabolites now shows it can identify autism with 90% sensitivity, producing no false positives in a multi-state study of nearly one hundred children.
- The metabolites measured — altered forms of serotonin and dopamine — may directly explain autism's core features, suggesting the gut microbiome is not a bystander but a biological driver.
- The test is already moving toward clinical use through a UK partner laboratory, even as researchers caution that larger, more diverse validation studies are essential before widespread adoption.
- Beyond diagnosis, the biological framing the test offers could dissolve the stigma and parental shame that sometimes delay families from seeking help in the first place.
A urine test developed at Arizona State University may soon offer families a faster, simpler path to understanding whether a young child is at risk for autism. Rather than relying solely on behavioral observation, the Microbially-Derived Metabolite System measures seventeen compounds produced by gut bacteria in children's urine. In an early study of nearly one hundred children ages two to eleven, drawn from four states, the test identified ninety percent of those with autism while generating no false positives among typically developing children — a result researchers describe as striking.
The work was led by Christina Flynn, a chemical engineer and parent of a child with autism, in collaboration with James Adams of ASU's Biodesign Center for Health Through Microbiomes. The differences between groups were dramatic: nearly every child with autism had at least one metabolite measuring one hundred to one thousand times higher than the ceiling found in control children. On average, children with autism showed three elevated metabolites; typically developing children showed none.
What gives the findings deeper significance is what those metabolites reveal. They include altered forms of serotonin and dopamine — neurotransmitters governing mood, cognition, and memory — and may help explain autism's hallmark features: social communication difficulties, anxiety, and attention challenges. The researchers propose a new autism subtype, ASD-MDM, which they estimate encompasses roughly ninety percent of cases.
The practical stakes are high. Earlier identification consistently leads to better outcomes, and a biological screening tool could move children to the front of diagnostic queues. Flynn has emphasized that framing autism as a biological condition — rather than a behavioral one — could reduce the shame that sometimes prevents parents from seeking help. The test is already available internationally through a UK partner laboratory, and Flynn now leads a newly certified Autism Diagnostics Laboratory.
Important caveats remain. The study sample was moderate in size, and broader validation across diverse populations is needed before clinical adoption at scale. Elevated metabolites are associated with autism symptoms but do not prove causation, and microbiota-based therapies remain in early investigation. Still, for the one in thirty-one American children affected by autism — and for the families enduring the long wait for answers — even a modest shortening of that gap carries profound weight.
A urine test may soon tell parents whether their young child is at risk for autism—not through behavioral observation or lengthy clinical evaluation, but through a simple measurement of compounds produced by bacteria in the gut. Researchers at Arizona State University have developed a screening tool that detects seventeen microbial metabolites in children's urine, and early results suggest the test can identify autism with striking accuracy: it caught ninety percent of children with autism in their study while producing no false alarms among typically developing children.
The test, called the Microbially-Derived Metabolite System, emerged from doctoral research by Christina Flynn, a chemical engineer who is herself a parent of a child with autism. Working with collaborators including James Adams, a researcher at ASU's Biodesign Center for Health Through Microbiomes, Flynn's team measured metabolite levels in fifty-two children diagnosed with autism spectrum disorder and forty-seven typically developing children, all between ages two and eleven, drawn from Arizona, Massachusetts, Tennessee, and Texas. The differences were unmistakable. Nearly every child with autism had at least one metabolite exceeding the highest level found in the control group—some measuring one hundred to one thousand times higher. On average, children with autism had about three elevated metabolites; typically developing children had none.
What makes this finding significant is not just the accuracy of the test, but what it reveals about the biology underlying autism. The metabolites the researchers measured are produced by the gut microbiome and include altered versions of serotonin and dopamine, neurotransmitters that regulate mood, cognition, and memory. Adams noted that these compounds could explain many of the core features of autism—difficulties with social communication, anxiety, depression, and attention problems. The research, published in Molecular Psychiatry, proposes a new autism subtype: ASD associated with microbially-derived metabolites, or ASD-MDM, which encompasses roughly ninety percent of autism cases. About ten percent of children with autism in the study had normal metabolite levels but other metabolic abnormalities possibly linked to genetic disorders.
The practical implications are substantial. Current autism diagnosis relies on behavioral assessment, and families often endure long waits for evaluation and answers. Earlier identification is consistently linked to better developmental outcomes, whether through medical, behavioral, or educational intervention. A urine test could move children to the front of diagnostic queues and, critically, reframe autism in parents' minds. Flynn emphasized that detecting autism through a biological marker—rather than through behavioral observation—could reduce the shame and diagnostic hesitancy some parents experience, the fear that they are somehow failing their children. If autism is biology, not parenting, the barrier to seeking help dissolves.
The test is not a standalone diagnosis; researchers are careful to say it serves as a screening and triage tool. But it is already moving toward real-world use. A partner laboratory in the United Kingdom, Analutos, is offering the urine test internationally. Flynn now serves as research director for a newly launched CLIA-certified Autism Diagnostics Laboratory and as a senior research scientist for Gut Brain Axis Therapeutics. For children already diagnosed, the test could help clinicians understand underlying biological factors and track how interventions affect the body over time.
Still, significant questions remain. The study sample was moderate in size, and researchers emphasize that broader validation across larger and more diverse populations is essential before widespread clinical adoption. Preliminary research suggests that microbiota-based therapies—including microbiota transplant—may reduce certain metabolite levels and improve symptoms, but rigorous clinical trials are needed. The researchers caution that elevated metabolites are associated with autism symptoms but do not prove causation.
Yet the potential is real. Autism affects an estimated one in thirty-one children in the United States, with a lifetime care cost averaging 3.6 million dollars per person. For many families, the hardest part is the waiting—the uncertainty, the not knowing. If a urine test can shorten that gap, even slightly, it changes the trajectory of early childhood. Flynn put it plainly: earlier intervention can genuinely help. The question now is whether this test can be validated and scaled to reach the families who need it most.
Notable Quotes
Eighty to ninety percent of children with autism have extremely high levels of one or more microbially derived metabolites. Using this test will tell you which young children are at high risk for being diagnosed with autism.— Christina Flynn, first author of the study
These are two key neurotransmitters that affect mood, cognition and memory. This could explain many of the symptoms and co-occurring symptoms in children with autism—their social communication, anxiety, depression and attention.— James Adams, corresponding author
The Hearth Conversation Another angle on the story
Why does the gut microbiome matter so much for autism? It seems like an odd connection.
The metabolites—these small molecules the bacteria produce—they're basically altered versions of serotonin and dopamine. Those are the neurotransmitters that run mood, cognition, memory. If a child's gut is producing too much of these altered versions, it could be flooding their system with signals that affect how their brain develops and functions.
So you're saying the bacteria are making fake neurotransmitters?
Not fake, exactly. Real compounds that mimic or interfere with the real neurotransmitters. Eighty to ninety percent of the children with autism in this study had extremely high levels of at least one of these metabolites. That's a striking pattern.
But does that mean the metabolites cause autism, or just that they're present in children who have autism?
That's the careful distinction the researchers make. They found a strong association, but they're not claiming causation. About ninety percent of autism cases seem to involve these elevated metabolites, but ten percent don't. And some of those ten percent have other metabolic problems entirely. It's not a simple one-to-one relationship.
What changes if parents can get this urine test result early?
Everything, potentially. Right now, diagnosis depends on behavioral observation, and families wait months or years for answers. A urine test could move a child to the front of the line for evaluation and early intervention. And psychologically, it reframes autism as a biological condition, not a parenting failure. That alone could reduce the shame and hesitation some parents feel about seeking help.
Is the test ready to use in clinics now?
It's available through some partner labs internationally, but researchers are clear that more validation is needed before it becomes standard. The study was relatively small. They need to test it across larger, more diverse populations. But the fact that it's already being offered somewhere shows momentum.